ExodusPoint Capital Management LP bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 102,351 shares of the biotechnology company's stock, valued at approximately $1,755,000.
Several other institutional investors also recently modified their holdings of ADMA. Vanguard Group Inc. raised its holdings in shares of ADMA Biologics by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock worth $312,109,000 after purchasing an additional 80,302 shares during the period. State Street Corp grew its position in shares of ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock valued at $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of ADMA Biologics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock valued at $93,187,000 after purchasing an additional 50,399 shares during the period. Perpetual Ltd purchased a new stake in ADMA Biologics during the 4th quarter worth about $62,300,000. Finally, Lord Abbett & CO. LLC purchased a new position in ADMA Biologics during the 3rd quarter valued at about $61,858,000. 75.68% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.
Get Our Latest Research Report on ADMA
ADMA Biologics Stock Up 6.7 %
Shares of ADMA stock traded up $1.30 during midday trading on Monday, reaching $20.70. 936,610 shares of the stock were exchanged, compared to its average volume of 3,552,966. The firm has a market cap of $4.89 billion, a PE ratio of 73.93 and a beta of 0.53. The company's 50 day moving average is $17.78 and its two-hundred day moving average is $18.15. ADMA Biologics, Inc. has a 1 year low of $5.91 and a 1 year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Read More
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
